albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Following this failure, a larger-scale version of the State Wula Agency was attempted in 1938 with the creation of the state-owned Xikang Animal Transport Company. This too had dismal results, as according to Liu (writing in a 1940 article), animals died en masse because Han colonists did not know how to take care of them and Kham herders had no incentive to do so. Once again, corruption was an issue, and the company was dissolved within a year after spending over 100,000 yuan. Despite this level of spending, it also suffered from a lack of veterinary medicine. A major debate over the wula system began after the collapse of both initiatives. One faction, led by Ren Zhuo, continued to call for abolishing the system to make way for state enterprise, Liu Wenhui, however, argued that the system would have to be kept and regulated due to the prior failures, and because it was the only major means of transportation in Kham. Another faction including Jiang Junzhang and the Frontier Administration Planning Commission argued for giving indigenous herders and other local voices more ownership and roles in company activities. There was a major ethnic dimension within this debate, because the anti-wula faction targeted the Kham herdsmen for their "obstinate" behavior and their control over the transport system.
A clinical trial protocol is a document used to define and manage the trial. It is prepared by a panel of experts. All study investigators are expected to strictly observe the protocol. The protocol describes the scientific rationale, objective(s), design, methodology, statistical considerations and organization of the planned trial. Details of the trial are provided in documents referenced in the protocol, such as an investigator's brochure. The protocol contains a precise study plan to assure safety and health of the trial subjects and to provide an exact template for trial conduct by investigators. This allows data to be combined across all investigators/sites. The protocol also informs the study administrators (often a contract research organization). The format and content of clinical trial protocols sponsored by pharmaceutical, biotechnology or medical device companies in the United States, European Union, or Japan have been standardized to follow Good Clinical Practice guidance issued by the International Conference on Harmonisation (ICH). Regulatory authorities in Canada, China, South Korea, and the UK also follow ICH guidelines. Journals such as Trials, encourage investigators to publish their protocols.
=== Discovery chemistry === BioDuro’s chemistry division supports medicinal chemistry, hit-to-lead, lead optimization, and synthetic route development. Its laboratories carry out small-molecule synthesis, peptide synthesis, and bioconjugation, including payload–linker development for antibody- drug conjugate (ADC) programs. The chemistry group works closely with DMPK and biology teams to support iterative design and structure- activity relationship (SAR) cycles.
Sources: en.wikipedia.org
=== Paleontology === Although the word dinosaur can be used pejoratively to describe something that is becoming obsolete due to failing to adapt to changing conditions, non-avian dinosaurs did not become extinct due to being generally maladapted or unable to cope with normal climatic change, a view found in many older textbooks. Moreover, not all dinosaurs are extinct (see below). Dinosaurs are not extinct, as birds are classified within the theropod dinosaur lineage. The word dinosaur is commonly used to refer only to non-avian dinosaurs, reflecting an outdated conception of the ancestry of avian dinosaurs, the birds. The evolutionary origin of birds was an open question in paleontology for over a century, but the modern scientific consensus is that birds evolved from small feathered theropods in the Jurassic. Not all dinosaur lineages were cut short at the end of the Cretaceous during the Cretaceous–Paleogene extinction event, and over 11,000 species of avian theropods survive as part of the modern fauna. Dinosaurs, pterosaurs, and ichthyosaurs were not cold-blooded. Dinosaur thermoregulation is a topic of ongoing study. However, their high growth rates and the presence of dinosaur fossils in cold polar climates make cold-bloodedness implausible. Pterosaurs are inferred to be warm-blooded because they had a hair-like body covering, a trait absent in modern cold-blooded animals. Estimates of ichthyosaur body temperature are similar to marine mammals in every climate.
=== Software wallets === Software wallets are software applications that allow users to manage and transfer digital assets, and sign messages. There are several modes in which software wallets can operate. They have an inverse relationship with regard to trustlessness and computational requirements.
=== Bosnia and Herzegovina === Following the general election on 3 October 2010, a process of formation of Bosnia and Herzegovina's Council of Ministers had begun. The resulting election produced a fragmented political landscape without a coalition of a parliamentary majority more than a year after the election. The centre-left Social Democratic Party, the largest party in the Federation of Bosnia and Herzegovina, and the Bosnian Serb autonomist Alliance of Independent Social Democrats, the largest party in Republika Srpska, each had 8 MPs of the total 42 MPs of the House of Representatives (28 from the Federation and 14 from Republika Srpska). Similarly, a crisis of government was also present at the local levels, as well as the Federal entity. In late 2011, the Council of Ministers (i.e. the national government) had been solved, however the country remained in a situation of perpetual political crisis, especially the Federation of Bosnia and Herzegovina. After months of dysfunction and arguments about legality, the entity's short-lived Federal Government had collapsed in February 2013. The 2014 unrest in Bosnia and Herzegovina was a series of demonstrations and riots that began in the northern town of Tuzla on 4 February 2014 but quickly spread to multiple cities in Bosnia and Herzegovina, including Sarajevo, Zenica, Mostar, Jajce, and Brčko, among others, for social reasons and with the aim of overthrowing the government. The riots were the most violent scenes the country had seen since the end of the Bosnian War in 1995.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.